TELA Bio, Inc. (TELA)
NGM · Healthcare · Medical Devices
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About TELA Bio, Inc.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 20.7M | 20.9M | 19.1M | 19.3M |
| Gross Profit | 14.0M | 13.8M | 12.5M | 13.9M |
| Operating Income | (7.6M) | (6.6M) | (10.5M) | (9.3M) |
| Net Income | (8.6M) | (9.0M) | (12.3M) | (11.3M) |
| Diluted EPS | $-0.19 | $-0.17 | $-0.21 | $-0.20 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 41.4M | 58.5M | 69.3M | 80.3M |
| Gross Profit | 27.0M | 40.1M | 46.5M | 54.3M |
| Operating Income | (39.0M) | (44.1M) | (41.7M) | (33.8M) |
| Net Income | (44.3M) | (46.7M) | (37.8M) | (38.8M) |
| Diluted EPS | $-2.72 | $-2.04 | $-1.33 | $-0.83 |